Determining the immunological basis for weakened SARS-CoV-2 vaccination outcomes

Project summary:

This study will establish the strength and durability of COVID-19 vaccine responses in people with two conditions that weaken the immune system: HIV and B cell lymphoma, a cancer of immune cells.

The study will compare how these conditions, which affect different parts of the immune system (HIV impairs ‘T cells’ and B cell cancers reduce ‘B cells’), affect vaccine response and will also compare a range of severity, from mildly to severely affected.

This data will help to better understand how these people respond to vaccines, and how this differs depending on how severely compromised their immune system is, to inform clinical decision making and input into policy for vaccine boosters.


Medical Research Council, UK Research and Innovation, Blood Cancer UK, NIHR UCLH Biomedical Research Centre

Leader researcher:

Dr Laura McCoy

Lead institution:


Vaccine type:


Recruitment for clinical trial open: